ERBB2 and breast carcinoma: In the LUX-Breast 3 phase II study, 121 HER2-positive breast cancer patients with progressive or recurrent brain metastases after trastuzumab and/or lapatinib treatment, were randomized into one of 3 cohorts: with SRS and afatinib alone, with SRS and afatinib plus vinorelbine or with SRS and treatment of the physician’s choice [49].